Actor Portrayal
Help Your Patients Get Back in Range
KYZATREX®:
Twice-daily Oral Testosterone Replacement Therapy
KYZATREX is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
A good choice for your patients. A good decision for your practice.
Cash Only / No Prior Authorizations / No Insurance Hassles
The TRT Your Patients Want
“When I first discovered I had Low T, I went with pellet therapy. While pellets seemed fine at first, they eventually became too much of a hassle – the painful implant process, scar tissue buildup and activity restrictions just weren’t for me, especially when the effects started wearing off before the next dose. As soon as I heard there was an oral option, that’s when I switched to KYZATREX. I love the convenience of the capsules, and my testosterone levels are in the normal range! It’s made a real difference in how I feel.”
David W.
Real Patient Taking KYZATREX
Twice-daily, No Needles or Gels
The Convenience of KYZATREX Capsules
Embrace the ease of twice-daily KYZATREX capsules, a convenient form of testosterone treatment.
With KYZATREX, you can offer a therapy that:
- Eliminates administration pain
- Avoids the mess associated with gels
- Eradicates transference risks
KYZATREX’s capsule form is designed to deliver a straightforward approach to testosterone therapy. As a cash-pay medication, KYZATREX provides a convenient option and removes the complications of insurance.
Insights on Testosterone Therapy & KYZATREX
In this webinar, Dr. Andrew Sun explores the evolution of testosterone therapy and the growing role of oral options. He reviews clinical data on KYZATREX, discusses treatment considerations, and shares practical tips for managing patient expectations when starting oral testosterone therapy.
KYZATREX® Clinical Data
The efficacy of KYZATREX was evaluated in a 6-month open-label clinical study involving 139 hypogonadal men (median age of 50 years; range 22 to 66 years). The primary efficacy endpoint was the percentage of KYZATREX-treated patients with mean plasma total testosterone concentration (Cavg) over 24-hours within the normal range of 222-800 ng/dl on the final PK visit of the study at Day 90. KYZATREX demonstrated the following at Day 90:
Stay Informed
Receive
Communication
from KYZATREX
References:
- KYZATREX [prescribing information]. Raleigh, NC: Marius Pharmaceuticals; 2023.
- Data on file. Raleigh, NC: Marius Pharmaceuticals, 2020.
